Antiviral drug-resistant HBV
Top Cited Papers
- 27 June 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 46 (1) , 254-265
- https://doi.org/10.1002/hep.21698
Abstract
Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy. (HEPATOLOGY 2007;46:254–265.)Keywords
This publication has 73 references indexed in Scilit:
- Emergence of a Novel Lamivudine-Resistant Hepatitis B Virus Variant with a Substitution Outside the YMDD MotifAntimicrobial Agents and Chemotherapy, 2006
- European Multicenter Evaluation of High-Density DNA Probe Arrays for Detection of Hepatitis B Virus Resistance Mutations and Identification of GenotypesJournal of Clinical Microbiology, 2006
- Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B VirusAntimicrobial Agents and Chemotherapy, 2006
- Variant of Hepatitis B Virus with Primary Resistance to AdefovirNew England Journal of Medicine, 2006
- 490 High barrier to resistance results in no emergence of entecavir resistance in nucleoside-naïve subjects during the first two years of therapyJournal of Hepatology, 2006
- A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis BGastroenterology, 2005
- Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensationJournal of Hepatology, 2005
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragmentsJournal of Hepatology, 2004
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999